Lyfeunit Ketamine USP Grade

Pharmaceutical Grade Ketamine for Treatment-Resistant Depression. Welcome to Lyfeunit Pharmaceutical Grade Ketamine Solutions, your trusted global supplier of USP Grade CAS No 1867-66-9 ketamine HCL powder , Ketamine Liquid injectionsVial sizes injections for Veterinary Use, Human use and Research Purposes, a Compounding Pharmacy.

Pharmaceutical Grade Ketamine Solutions

LyfeUnit: High-Purity Research & Therapeutic Ketamine

Medical Disclaimer: The information on LyfeUnit is for educational purposes only and does not constitute medical advice. Ketamine therapy involves risks and should only be used under clinical supervision. Read our full Medical Disclaimer.

USP COMPLIANT

HIPAA PROTECTED

CAS: 1867-66-9

PHARMACEUTICAL GRADE

At LyfeUnit, we provide Trusted Ketamine Sourcing & Information to bridge the gap between clinical research and patient wellness. In 2026, the Pharmaceutical Purity of your sourcing is the single most important factor in achieving Therapeutic Efficacy. Our mission is to provide premium solutions for individuals struggling with Treatment-Resistant Depression (TRD) and neuropathic pain.

Uncompromising High-Purity Ketamine HCL Sourcing

Not all treatments are equal. LyfeUnit specializes in High-Purity Ketamine HCl, ensuring every formulation meets the rigorous standards required for modern Mental Health Support.

Technical SpecificationStandard DetailCAS Number1867-66-9 (Ketamine Hydrochloride)Molecular Formula$C_{13}H_{16}ClNO \cdot HCl$Quality StandardsUSP (United States Pharmacopeia) Grade / ISO 17025Purity Level≥ 99.0% Molecular Integrity

Clinical Research & The Science of Relief

Maximizing the 72-hour neuroplasticity window

The power of Ketamine lies in Neuroplasticity—the brain’s ability to create new neural connections. The 72-hour window is characterized by a surge in BDNF (Brain-Derived Neurotrophic Factor) and Glutamate modulation. This brief period of heightened plasticity allows for rapid “rewiring” of neural pathways associated with depressive rumination, offering a breakthrough for those who have failed traditional treatments.

  • Rapid Glutamate Modulation: Triggers immediate neurotransmitter repair and synaptogenesis.
  • The Integration Phase: Crucial post-session support to maximize the plasticity window for long-term breakthroughs.
  • Structural Brain Health: Moving beyond symptom masking to address the physical pathways of the brain.